PHATHOM PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Amortization of Debt Issuance Costs of $1.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $912.00K, a 24.25% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $844.00K, a 21.26% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $809.00K, a 28.62% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $775.00K, a 31.58% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2025 was $3.01M, a 37.50% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2024 was $2.19M, a 16.78% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2023 was $1.88M, a 11.04% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2022 was $2.11M, a 41.31% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $912.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.76M 10-Q · filed 2026-07-30 | $2.56M derived: sum of 3 quarters · filed 2026-07-30 | $3.34M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $844.00K 10-Q · filed 2026-04-30 | $1.65M derived: sum of 2 quarters · filed 2026-04-30 | $2.43M derived: sum of 3 quarters · filed 2026-04-30 | $3.16M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $809.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.58M derived: sum of 2 quarters · filed 2026-02-26 | $2.32M derived: sum of 3 quarters · filed 2026-07-30 | $3.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $775.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.51M derived: sum of 2 quarters · filed 2026-07-30 | $2.21M 10-Q · filed 2025-10-30 | $2.83M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $734.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.43M 10-Q · filed 2026-07-30 | $2.06M derived: sum of 3 quarters · filed 2026-07-30 | $2.65M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $696.00K 10-Q · filed 2026-04-30 | $1.32M derived: sum of 2 quarters · filed 2026-04-30 | $1.91M derived: sum of 3 quarters · filed 2026-04-30 | $2.41M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.22M derived: sum of 2 quarters · filed 2026-02-26 | $1.72M derived: sum of 3 quarters · filed 2026-02-26 | $2.19M 10-K · filed 2026-02-26 |
| 2024-09-30 | $589.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.09M derived: sum of 2 quarters · filed 2025-10-30 | $1.56M 10-Q · filed 2025-10-30 | $2.13M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $974.00K 10-Q · filed 2025-08-07 | $1.54M derived: sum of 3 quarters · filed 2025-08-07 | $2.08M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $474.00K 10-Q · filed 2025-05-01 | $1.04M derived: sum of 2 quarters · filed 2025-05-01 | $1.58M derived: sum of 3 quarters · filed 2025-05-01 | $1.85M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.11M derived: sum of 2 quarters · filed 2025-03-06 | $1.38M derived: sum of 3 quarters · filed 2025-03-06 | $1.88M 10-K · filed 2025-03-06 |
| 2023-09-30 | $542.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $815.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.31M 10-Q · filed 2024-11-07 | $1.81M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $273.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $769.00K 10-Q · filed 2024-08-08 | $1.27M derived: sum of 3 quarters · filed 2024-08-08 | $1.83M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $496.00K 10-Q/A · filed 2024-06-14 | $993.00K derived: sum of 2 quarters · filed 2024-06-14 | $1.56M derived: sum of 3 quarters · filed 2024-06-14 | $2.09M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $497.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $1.06M derived: sum of 2 quarters · filed 2024-06-14 | $1.59M derived: sum of 3 quarters · filed 2024-06-14 | $2.11M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $564.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.09M derived: sum of 2 quarters · filed 2023-11-09 | $1.61M 10-Q · filed 2023-11-09 | $2.12M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $531.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.05M 10-Q · filed 2023-08-10 | $1.56M derived: sum of 3 quarters · filed 2023-08-10 | $3.95M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $518.00K 10-Q · filed 2023-05-10 | $1.02M derived: sum of 2 quarters · filed 2023-05-10 | $3.42M derived: sum of 3 quarters · filed 2023-05-10 | $3.75M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $507.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $2.90M derived: sum of 2 quarters · filed 2023-02-28 | $3.23M derived: sum of 3 quarters · filed 2023-02-28 | $3.60M 10-K · filed 2023-02-28 |
| 2021-09-30 | $2.39M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | $2.72M derived: sum of 2 quarters · filed 2022-11-09 | $3.09M 10-Q/A · filed 2022-11-09 | $3.46M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $698.00K 10-Q · filed 2022-08-02 | $1.07M derived: sum of 3 quarters · filed 2022-08-02 | $1.43M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $364.00K 10-Q · filed 2022-05-10 | $733.00K derived: sum of 2 quarters · filed 2022-05-10 | $1.09M derived: sum of 3 quarters · filed 2022-05-10 | $1.44M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $369.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $729.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.07M derived: sum of 3 quarters · filed 2022-03-01 | $1.27M 10-K · filed 2022-03-01 |
| 2020-09-30 | $360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $705.00K derived: sum of 2 quarters · filed 2021-11-08 | $904.00K 10-Q · filed 2021-11-08 | $1.07M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $345.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $544.00K 10-Q · filed 2021-08-10 | $710.00K derived: sum of 3 quarters · filed 2021-08-10 | $872.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $199.00K 10-Q · filed 2021-05-11 | $365.00K derived: sum of 2 quarters · filed 2021-05-11 | $527.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $328.00K derived: sum of 2 quarters · filed 2021-03-30 | $409.00K 10-K · filed 2021-03-30 | |
| 2019-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $243.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $81.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |